OOIR: Observatory of International Research

Papers

(The TQCC of Circulation-Heart Failure is 11. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-05-01 to 2024-05-01.)

Article	Citations
Management of Acute Myocarditis and Chronic Inflammatory Cardiomyopathy	358
Invasive Hemodynamic Assessment and Classification of In-Hospital Mortality Risk Among Patients With Cardiogenic Shock	157
Understanding the Complexity of Heart Failure Risk and Treatment in Black Patients	139
Lower Rates of Heart Failure and All-Cause Hospitalizations During Pulmonary Artery Pressure-Guided Therapy for Ambulatory Heart Failure	124
Trends in 30- and 90-Day Readmission Rates for Heart Failure	118
Multidisciplinary Cardiac Rehabilitation and Long-Term Prognosis in Patients With Heart Failure	115
Polypharmacy in Older Adults Hospitalized for Heart Failure	102
Cardioprotective Effects of Sirtuin-1 and Its Downstream Effectors	102
Prevalence and Incidence of Heart Failure Among Urban Patients in China: A National Population-Based Analysis	88
Predicting the Risk of Right Ventricular Failure in Patients Undergoing Left Ventricular Assist Device Implantation	86
Ketone Ester Treatment Improves Cardiac Function and Reduces Pathologic Remodeling in Preclinical Models of Heart Failure	85
Approach to Acute Cardiovascular Complications in COVID-19 Infection	81
Incidence of New-Onset and Worsening Heart Failure Before and After the COVID-19 Epidemic Lockdown in Denmark	81
Clinical Phenotypes and Prognosis of Dilated Cardiomyopathy Caused by Truncating Variants in the TTN Gene	77
Cardiogenic Shock and Hyperinflammatory Syndrome in Young Males With COVID-19	76
Sex Disparities in the Management and Outcomes of Cardiogenic Shock Complicating Acute Myocardial Infarction in the Young	69
Long-Term Survival With Tafamidis in Patients With Transthyretin Amyloid Cardiomyopathy	68
Intra-Aortic Balloon Pump Bridging to Heart Transplantation	59
Chronically Elevating Circulating Ketones Can Reduce Cardiac Inflammation and Blunt the Development of Heart Failure	58
Proteomic and Functional Studies Reveal Detyrosinated Tubulin as Treatment Target in Sarcomere Mutation-Induced Hypertrophic Cardiomyopathy	56
Representation of Women Authors in International Heart Failure Guidelines and Contemporary Clinical Trials	53
Secondary Impact of the COVID-19 Pandemic on Patients With Heart Failure	51
Obese-Inflammatory Phenotypes in Heart Failure With Preserved Ejection Fraction	49
Clinical Outcomes Associated With Acute Mechanical Circulatory Support Utilization in Heart Failure Related Cardiogenic Shock	49
Inflammation and Circulating Natriuretic Peptide Levels	48

Temporal Trend of Age at Diagnosis in Hypertrophic Cardiomyopathy	46
Invasive Right Ventricular Pressure-Volume Analysis: Basic Principles, Clinical Applications, and Practical Recommendations	46
Study Design and Rationale of EXPLORER-HCM	46
Prognostic Value of Secreted Frizzled-Related Protein 5 in Heart Failure Patients With and Without Type 2 Diabetes Mellitus	44
Epicardial Adipose Tissue and Outcome in Heart Failure With Mid-Range and Preserved Ejection Fraction	44
Risk Profiles in Heart Failure	44
Excess 30-Day Heart Failure Readmissions and Mortality in Black Patients Increases With Neighborhood Deprivation	43
Defining Shock and Preshock for Mortality Risk Stratification in Cardiac Intensive Care Unit Patients	42
Referral Criteria to Palliative Care for Patients With Heart Failure	41
Renal Sympathetic Denervation in Patients With Heart Failure With Preserved Ejection Fraction	39
Efficacy and Safety of Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction According to Age: The DELIVER Trial	38
The Upcoming Epidemic of Heart Failure in South Asia	37
Clinical and Hemodynamic Associations and Prognostic Implications of Ventilatory Efficiency in Patients With Preserved Left Ventricular Systolic Function	37
Infection-Related Hospitalization in Heart Failure With Reduced Ejection Fraction	37
Advanced Pulmonary and Cardiac Support of COVID-19 Patients	36
Factors Associated With Racial and Ethnic Diversity Among Heart Failure Trial Participants: A Systematic Bibliometric Review	35
Gut Microbiota-Generated Phenylacetylglutamine and Heart Failure	35
Characterizing Sex Differences in Physical Frailty Phenotypes in Heart Failure	34
Effect of Empagliflozin as an Add-On Therapy on Decongestion and Renal Function in Patients With Diabetes Hospitalized for Acute Decompensated Heart Failure	34
Metabolomic Profiles and Heart Failure Risk in Black Adults: Insights From the Jackson Heart Study	33
Yellow Wine Polyphenolic Compound Protects Against Doxorubicin-Induced Cardiotoxicity by Modulating the Composition and Metabolic Function of the Gut Microbiota	32
Defects in the Proteome and Metabolome in Human Hypertrophic Cardiomyopathy	32
Psychosocial Risk and Its Association With Outcomes in Continuous-Flow Left Ventricular Assist Device Patients	32
Extracardiac Abnormalities of Preload Reserve	32
Myocardial Tissue Reverse Remodeling After Guideline-Directed Medical Therapy in Idiopathic Dilated Cardiomyopathy	32
Randomized Placebo-Controlled Trial of Ferric Carboxymaltose in Heart Failure With Iron Deficiency: Rationale and Design	32
Understanding Cardiogenic Shock Severity and Mortality Risk Assessment	32
NAD ⁺ Redox Imbalance in the Heart Exacerbates Diabetic Cardiomyopathy	31
Right Heart Failure Following Left Ventricular Device Implantation: Natural History, Risk Factors, and Outcomes: An Analysis of the STS INTERMACS Database	31
Disparity in the Setting of Incident Heart Failure Diagnosis	30
Better Understanding the Disparity Associated With Black Race in Heart Transplant Outcomes	30
Reverse Cardiac Remodeling and Outcome After Initiation of Sacubitril/Valsartan	29
Cardiac Power Output Revisited	29
Prognostic Value of Dynamic Changes in Pulmonary Congestion During Exercise Stress Echocardiography in Heart Failure With Preserved Ejection Fraction	29
Enhanced Expression and Function of Renal SGLT2 (Sodium-Glucose Cotransporter 2) in Heart Failure: Role of Renal Nerves	29
Elevated Angiotensin 1–7/Angiotensin II Ratio Predicts Favorable Outcomes in Patients With Heart Failure	29
Skeletal Muscle Function, Structure, and Metabolism in Patients With Heart Failure With Reduced Ejection Fraction and Heart Failure With Preserved Ejection Fraction	29
Global Differences in Heart Failure With Preserved Ejection Fraction	28
Reference Ranges for NT-proBNP (N-Terminal Pro-B-Type Natriuretic Peptide) and Risk Factors for Higher NT-proBNP Concentrations in a Large General Population Cohort	28
Current Limitations of Invasive Exercise Hemodynamics for the Diagnosis of Heart Failure With Preserved Ejection Fraction	27
Association Between Coffee Intake and Incident Heart Failure Risk	27
Multiparametric Implantable Cardioverter-Defibrillator Algorithm for Heart Failure Risk Stratification and Management: An Analysis in Clinical Practice	27
The Value of Passive Leg Raise During Right Heart Catheterization in Diagnosing Heart Failure With Preserved Ejection Fraction	27
Comprehensive Proteomics Profiling Reveals Circulating Biomarkers of Hypertrophic Cardiomyopathy	27
Aptamer-Based Proteomic Platform Identifies Novel Protein Predictors of Incident Heart Failure and Echocardiographic Traits	27
Association Between Angiotensin Receptor–Neprilysin Inhibition, Cardiovascular Biomarkers, and Cardiac Remodeling in Heart Failure With Reduced Ejection Fraction	27
Clinical Characteristics and Predictors of In-Hospital Mortality in Patients With Cardiogenic Shock: Results From the RESCUE Registry	26
Efficacy and Safety of Sacubitril/Valsartan in High-Risk Patients in the PIONEER-HF Trial	26
Intra-Aortic Balloon Pumping in Acute Decompensated Heart Failure With Hypoperfusion: From Pathophysiology to Clinical Practice	25
Prognostic Role of Prior Heart Failure Hospitalization Among Patients Hospitalized for Worsening Chronic Heart Failure	25

Clinically Translatable Prevention of Anthracycline Cardiotoxicity by Dexrazoxane Is Mediated by Topoisomerase II Beta and Not Metal Chelation	24
Improvement in Left Ventricular Ejection Fraction in Outpatients With Heart Failure With Reduced Ejection Fraction	24
Phosphodiesterase 9a Inhibition in Mouse Models of Diastolic Dysfunction	24
Clinical Characteristics and Outcomes of Adults With a History of Heart Failure Hospitalized for COVID-19	24
Framework to Classify Reverse Cardiac Remodeling With Mechanical Circulatory Support: The Utah-Inova Stages	24
Racial Inequities in Access to Ventricular Assist Device and Transplant Persist After Consideration for Preferences for Care: A Report From the REVIVAL Study	23
In Vitro and In Vivo Evaluation of a Small-Molecule APJ (Apelin Receptor) Agonist, BMS-986224, as a Potential Treatment for Heart Failure	23
Practice Patterns and Patient Outcomes After Widespread Adoption of Remote Heart Failure Care	23
Mitochondrial Sirtuin-3 (SIRT3) Prevents Doxorubicin-Induced Dilated Cardiomyopathy by Modulating Protein Acetylation and Oxidative Stress	23
Role of Pulmonary Artery Wedge Pressure Saturation During Right Heart Catheterization	22
Transcriptomic Analysis of Right Ventricular Remodeling in Two Rat Models of Pulmonary Hypertension	22
Novel Trial Design: CHIEF-HF	22
Bridging With Extracorporeal Membrane Oxygenation Under the New Heart Allocation System: A United Network for Organ Sharing Database Analysis	22
Cardiogenic Shock From Heart Failure Versus Acute Myocardial Infarction: Clinical Characteristics, Hospital Course, and 1-Year Outcomes	22
Virtual Versus In-Person Visits and Appointment No-Show Rates in Heart Failure Care Transitions	22
Race- and Sex-Specific Population Attributable Fractions of Incident Heart Failure	22
Kidney Disease Biomarkers Improve Heart Failure Risk Prediction in the General Population	21
Exercise Training Protects Against Heart Failure Via Expansion of Myeloid-Derived Suppressor Cells Through Regulating IL-10/STAT3/S100A9 Pathway	21
Characteristics and Outcomes of COVID-19 in Patients on Left Ventricular Assist Device Support	21
Early Outcomes of Heart Transplantation Using Donation After Circulatory Death Donors in the United States	21
Development of Advanced Heart Failure: A Population-Based Study	21
Heart Failure and Shared Decision-Making: Patients Open to Medication-Related Cost Discussions	21
Brain-Derived Neurotrophic Factor Improves Impaired Fatty Acid Oxidation Via the Activation of Adenosine Monophosphate-Activated Protein Kinase-ɑ – Proliferator-Activated Receptor-r Coactivator-1ɑ Sig	20
Transcatheter Mitral Valve Repair in Patients With and Without Cardiac Resynchronization Therapy	20
Cardiac Microvascular Endothelial Cells in Pressure Overload–Induced Heart Disease	20
Cardiolipin Remodeling Defects Impair Mitochondrial Architecture and Function in a Murine Model of Barth Syndrome Cardiomyopathy	20
Current Approach to the Diagnosis of Sarcopenia in Heart Failure: A Narrative Review on the Role of Clinical and Imaging Assessments	20
Alcohol Intake in Patients With Cardiomyopathy and Heart Failure: Consensus and Controversy	20
Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to N-Terminal Pro-B-Type Natriuretic Peptide: Insights From the DAPA-HF Trial	20
Comparison of Outcome Adjudication by Investigators and by a Central End Point Committee in Heart Failure Trials	19
CRD-733, a Novel PDE9 (Phosphodiesterase 9) Inhibitor, Reverses Pressure Overload–Induced Heart Failure	19
Predictive Accuracy of Heart Failure-Specific Risk Equations in an Electronic Health Record-Based Cohort	19
Association of Hyper-Polypharmacy With Clinical Outcomes in Heart Failure With Preserved Ejection Fraction	18
Virus-Negative Myopericarditis in Human Coronavirus Infection	18
Risk-Based Approach for the Prediction and Prevention of Heart Failure	18
Mode of Death in Patients With Heart Failure and Preserved Ejection Fraction: Insights From PARAGON-HF Trial	18
Protein Aggregation Is an Early Manifestation of Phospholamban p.(Arg14del)–Related Cardiomyopathy: Development of PLN-R14del–Related Cardiomyopathy	18
Effect of Empagliflozin on Blood Volume Redistribution in Patients With Chronic Heart Failure and Reduced Ejection Fraction: An Analysis From the Empire HF Randomized Clinical Trial	18
Association of Pulmonary Artery Pulsatility Index With Adverse Cardiovascular Events Across a Hospital-Based Sample	18
Insights Into Myocardial Oxygenation and Cardiovascular Magnetic Resonance Tissue Biomarkers in Heart Failure With Preserved Ejection Fraction	18
Estrogen Receptor-β Agonists Modulate T-Lymphocyte Activation and Ameliorate Left Ventricular Remodeling During Chronic Heart Failure	18
Polygenic Score for β-Blocker Survival Benefit in European Ancestry Patients With Reduced Ejection Fraction Heart Failure	18
Racial and Ethnic Differences in Biomarkers, Health Status, and Cardiac Remodeling in Patients With Heart Failure With Reduced Ejection Fraction Treated With Sacubitril/Valsartan	18
Use of Extracorporeal Membrane Oxygenation as Bridge to Replacement Therapies in Cardiogenic Shock: Insights From the Extracorporeal Life Support Organization	17
Defining a Clinically Important Change in 6-Minute Walk Distance in Patients With Heart Failure and Mitral Valve Disease	17
Transition of a Large Tertiary Heart Failure Program in Response to the COVID-19 Pandemic	17
Longitudinal Changes in Cardiac Structure and Function From Adolescence to Young Adulthood in Participants With Type 2 Diabetes Mellitus	17
Endothelial Stromal PD-L1 (Programmed Death Ligand 1) Modulates CD8 ⁺ T-Cell Infiltration After Heart Transplantation	17
Intermittent Occlusion of the Superior Vena Cava to Improve Hemodynamics in Patients With Acutely Decompensated Heart Failure: The VENUS-HF Early Feasibility Study	16
MiR-150 Attenuates Maladaptive Cardiac Remodeling Mediated by Long Noncoding RNA MIAT and Directly Represses Profibrotic Hoxa4	16
Transcutaneous Vagus Nerve Stimulation Ameliorates the Phenotype of Heart Failure With Preserved Ejection Fraction Through Its Anti-Inflammatory Effects	16
Intersection of Heart Failure and Pregnancy: Beyond Peripartum Cardiomyopathy	16
Virome Sequencing in Patients With Myocarditis	16
Treatment Differences in Chronic Heart Failure Patients With Reduced Ejection Fraction According to Blood Pressure	16
Association of the Novel Inflammatory Marker GlycA and Incident Heart Failure and Its Subtypes of Preserved and Reduced Ejection Fraction	16
Synergistic Impact of Systolic Blood Pressure and Perfusion Status on Mortality in Acute Heart Failure	16
Novel Small-Molecule Troponin Activator Increases Cardiac Contractile Function Without Negative Impact on Energetics	16
Automated E-Counseling for Chronic Heart Failure	15
Mineralocorticoid Receptor in Smooth Muscle Contributes to Pressure Overload–Induced Heart Failure	15
FGF21 (Fibroblast Growth Factor 21) Defines a Potential Cardiohepatic Signaling Circuit in End-Stage Heart Failure	15
Racial Differences in Diuretic Efficiency, Plasma Renin, and Rehospitalization in Subjects With Acute Heart Failure	15
COP9 Signalosome Suppresses RIPK1-RIPK3–Mediated Cardiomyocyte Necroptosis in Mice	15
Durable Mechanical Circulatory Support in Patients With Amyloid Cardiomyopathy	15
How Patients With Heart Failure Perform Daily Life Activities	15
Immunity and Stress Responses Are Induced During Ex Situ Heart Perfusion	14
Impairments in Blood Pressure Regulation and Cardiac Baroreceptor Sensitivity Among Patients With Heart Failure Supported With Continuous-Flow Left Ventricular Assist Devices	14
Right Heart Phenotype in Heart Failure With Preserved Ejection Fraction	14
Levels of Trimethylamine N-Oxide Remain Elevated Long Term After Left Ventricular Assist Device and Heart Transplantation and Are Independent From Measures of Inflammation and Gut Dysbiosis	14
Nexilin Is Necessary for Maintaining the Transverse-Axial Tubular System in Adult Cardiomyocytes	14
Hemodynamic Effects of Cyclic Guanosine Monophosphate-Dependent Signaling Through β3 Adrenoceptor Stimulation in Patients With Advanced Heart Failure: A Randomized Invasive Clinical Trial	14
Acute Hemodynamic Effects and Tolerability of Phosphodiesterase-1 Inhibition With ITI-214 in Human Systolic Heart Failure	13
False-Positive ^99m Technetium-Pyrophosphate Scintigraphy in Two Patients With Hypertrophic Cardiomyopathy	13
Exception Status Listing in the New Adult Heart Allocation System: A New Solution to an Old Problem?	13
Prognostic Value of Elevated Levels of Plasma N-Acetylneuraminic Acid in Patients With Heart Failure	13
Potential Role of Natriuretic Response to Furosemide Stress Test During Acute Heart Failure	13
Detection of Left Atrial Myopathy Using Artificial Intelligence–Enabled Electrocardiography	13
Clinical and Genetic Investigations of 109 Index Patients With Dilated Cardiomyopathy and 445 of Their Relatives	13
Cardiac and Noncardiac Disease Burden and Treatment Effect of Sacubitril/Valsartan	13
Patient Characteristics, Clinical Outcomes, and Effect of Dapagliflozin in Relation to Duration of Heart Failure	13
Out-of-Pocket Costs for SGLT-2 (Sodium-Glucose Transport Protein-2) Inhibitors in the United States	13

Safety of Endomyocardial Biopsy in New-Onset Acute Heart Failure Requiring Veno-Arterial Extracorporeal Membrane Oxygenation	13
Temporal Trends of Heart Failure Hospitalizations in Cardiology Versus Noncardiology Wards According to Ejection Fraction: 16-Year Data From the SwedeHF Registry	13
Multimarker Analysis of Serially Measured GDF-15, NT-proBNP, ST2, GAL-3, cTnI, Creatinine, and Prognosis in Acute Heart Failure	12
Determinants of Survival in Older Adults With Congenital Heart Disease Newly Hospitalized for Heart Failure	12
Clinical Profile and Health Disparities in a Multiethnic Cohort of Patients With Hypertrophic Cardiomyopathy	12
Participation in a Heart Failure Clinical Trial	12
ERBB4 and Multiple MicroRNAs That Target ERBB4 Participate in Pregnancy-Related Cardiomyopathy	12
Intoxicated Donors and Heart Transplant Outcomes: Long-Term Safety	12
Vericiguat and Health-Related Quality of Life in Patients With Heart Failure With Reduced Ejection Fraction: Insights From the VICTORIA Trial	12
Management of Hypertension in Patients With Ventricular Assist Devices: A Scientific Statement From the American Heart Association	12
Sarcopenic Obesity Is Associated With Reduced Cardiorespiratory Fitness Compared With Nonsarcopenic Obesity in Patients With Heart Failure With Reduced Ejection Fraction	12
Association of Sedentary Time and Incident Heart Failure Hospitalization in Postmenopausal Women	11
Skeletal Muscle Mass Recovery Early After Left Ventricular Assist Device Implantation in Patients With Advanced Systolic Heart Failure	11
Right Ventricular and Right Atrial Function Are Less Compromised in Pulmonary Hypertension Secondary to Heart Failure With Preserved Ejection Fraction: A Comparison With Pulmonary Arterial Hypertensio	11
Temporal Trends and Clinical Trial Characteristics Associated With the Inclusion of Women in Heart Failure Trial Steering Committees: A Systematic Review	11
Obesity and Outcomes Following Cardiogenic Shock Requiring Acute Mechanical Circulatory Support	11
Pulmonary Hypertension in Congenital Heart Disease: A Scientific Statement From the American Heart Association	11
Trends in Characteristics and Outcomes in Primary Heart Failure Hospitalizations Among Older Population in the United States, 2004 to 2018	11
Socioeconomic Disparities in Referral for Invasive Hemodynamic Evaluation for Advanced Heart Failure: A Nationwide Cohort Study	11
Association Between β-Blocker Use and Mortality/Morbidity in Patients With Heart Failure With Reduced, Midrange, and Preserved Ejection Fraction and Advanced Chronic Kidney Disease	11
Remodeling of the Purkinje Network in Congestive Heart Failure in the Rabbit	11
High-Intensity Interval Training Decreases Muscle Sympathetic Nerve Activity and Improves Peripheral Vascular Function in Patients With Heart Failure With Reduced Ejection Fraction	11
Diagnosis and Treatment of Right Heart Failure in Pulmonary Vascular Diseases: A National Heart, Lung, and Blood Institute Workshop	11
Sex-Specific Clinical Outcomes of the PACT-HF Randomized Trial	11
Sodium Restriction in Patients With Heart Failure: A Systematic Review and Meta-Analysis of Randomized Clinical Trials	11
Peripheral Venous Pressure-Assisted Exercise Stress Echocardiography in the Evaluation of Pulmonary Hypertension During Exercise in Patients With Suspected Heart Failure With Preserved Ejection Fracti	11
The RAISE Trial: A Novel Device and First-in-Man Trial	11
Targeting Preload in Heart Failure: Splanchnic Nerve Blockade and Beyond	11
Targeted Therapies in Pediatric and Adult Patients With Hypertrophic Heart Disease: From Molecular Pathophysiology to Personalized Medicine	11
Altered Enhancer and Promoter Usage Leads to Differential Gene Expression in the Normal and Failed Human Heart	11
Reduced Diuretic Dose in Patients Treated With Eplerenone	11
Epidemiology of Cardiogenic Shock in Hospitalized Adults With COVID-19: A Report From the American Heart Association COVID-19 Cardiovascular Disease Registry	11